Article
Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients.
Alimentary pharmacology & therapeutics - 1 Sept 2017
Curry M P, Tapper E B, Bacon B, Dieterich D, Flamm S L, Guest L, Kowdley K V, Lee Y, Milligan S, Tsai N, Younossi Z, Afdhal N H
Abstract excerpt
BACKGROUND: Treatment of genotype 1 hepatitis C virus (HCV) infection with combination direct acting anti-virals is associated with very high rates of sustained virological response (SVR). Daily combination of ledipasvir and sofosbuvir for 12 weeks is approved for the treatment of genotype 1 HCV patients, though noncirrhotic patients who are naïve to treatment with a baseline HCV RNA <6 million IU/mL can be...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.